Adrenomedullin augments the release and production of tissue factor pathway inhibitor in human aortic endothelial cells

Cardiovascular Research

Volumn 57, Issue 1, 2003, Pages 232-237

  Marutsuka, Kousuke ^a   Hatakeyama, Kinta ^a   Yamashita, Atsushi ^a   Sato, Yuichiro ^a   Sumiyoshi, Akinobu ^a   Asada, Yujiro ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

Anticoagulants; Arteries; Cell culture isolation; Endothelial function; Hemostasis

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 8 BROMO CYCLIC AMP; ADRENOMEDULLIN; ADRENOMEDULLIN[1-25]; ADRENOMEDULLIN[22-52]; CALCITONIN GENE RELATED PEPTIDE[8-37]; CALPHOSTIN C; CYCLOHEXIMIDE; DACTINOMYCIN; MONOCLONAL ANTIBODY; N(G) NITROARGININE METHYL ESTER; RECEPTOR BLOCKING AGENT; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOTTING; CARBOXY TERMINAL SEQUENCE; CELL CULTURE; CIRCULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN INTERACTION;

ADRENOMEDULLIN; ANTIBODIES, MONOCLONAL; AORTA; CELLS, CULTURED; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FLAVONOIDS; HUMANS; LIPOPROTEINS; NAPHTHALENES; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PEPTIDES; RECEPTORS, PEPTIDE; STIMULATION, CHEMICAL; VASODILATOR AGENTS;

EID: 0037215684     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(02)00612-0     Document Type: Article

References (36)

1. Kitamura K., Kangawa K., Kawamoto M., et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun. 192:1993;553-560.
2. Ichiki Y., Kitamura K., Kangawa K., et al. Distribution and characterization of immunoreactive adrenomedullin in porcine tissue, and isolation of adrenomedullin [26-52] and adrenomedullin [34-52] from porcine duodenum. J Biochem (Tokyo). 118:1995;765-770.
3. Washimine H., Asada Y., Kitamura K., et al. Immunohistochemical identification of adrenomedullin in human, rat, and porcine tissue. Histochem Cell Biol. 103:1995;251-254.
4. Asada Y., Hara S., Marutsuka K., et al. Novel distribution of adrenomedullin-immunoreactive cells in human tissues. Histochem Cell Biol. 112:1999;185-191.
5. Eto T., Kitamura K., Kato J. Biological and clinical roles of adrenomedullin in circulation control and cardiovascular diseases. Clin Exp Pharmacol Physiol. 26:1999;371-380.
6. Schiller N.K., Champion H.C., Hugghins S.Y., et al. Adrenomedullin does not inhibit human platelet aggregation. J Cardiovasc Pharmacol Ther. 3:1998;223-228.
7. Sugano T., Tsuji H., Masuda H., et al. Adrenomedullin inhibits angiotensin II-induced expression of tissue factor and plasminogen activator inhibitor-1 in cultured rat aortic endothelial cells. Arterioscler Thromb Vasc Biol. 21:2001;1078-1083.
8. Petersen L.C., Valentin S., Hedner U. Regulation of the extrinsic pathway system in health and disease: the role of factor VIIa and tissue factor pathway inhibitor. Thromb Res. 79:1995;1-47.
9. Broze G.J. Jr. Tissue factor pathway inhibitor. Thromb Haemost. 74:1995;90-93.
10. Fareed J., Hoppensteadt D.A., Bick R.L. An update on heparins at the beginning of the new millennium. Semin Thromb Hemost. 26:2000;5-21.
11. Sandset P.M., Bendz B., Hansen J.B. Physiological function of tissue factor pathway inhibitor and interaction with heparins. Haemostasis. 30:2000;48-56.
12. Wang P. Adrenomedullin in sepsis and septic shock. Shock. 10:1998;383-384.
13. Matsui E., Kitamura K., Yoshida M., et al. Biosynthesis and secretion of adrenomedullin and proadrenomedullin N-terminal 20 peptide in a rat model of endotoxin shock. Hypertens Res. 24:2001;543-549.
14. Kobayashi K., Kitamura K., Hirayama N., et al. Increased plasma adrenomedullin in acute myocardial infarction. Am Heart J. 131:1996;676-680.
15. Osterud B., Bjorklid E. The tissue factor pathway inhibitor in disseminated intravascular coagulation. Semin Thromb Hemost. 27:2001;667-674.
16. Asakura H., Ontachi Y., Mizutani T., et al. Elevated levels of free tissue factor pathway inhibitor antigen in cases of disseminated intravascular coagulation caused by various underlying diseases. Blood Coagul Fibrinolysis. 12:2001;1-8.
17. Yamamoto N., Ogawa H., Oshima S., et al. The effect of heparin on tissue factor and tissue factor pathway inhibitor in patients with acute myocardial infarction. Int J Cardiol. 75:2000;267-274.
18. Ohta H., Tsuji T., Asai S., et al. One-step direct assay for mature-type adrenomedullin with monoclonal antibodies. Clin Chem. 45:1999;244-251.
19. Hara S., Asada Y., Hatakeyama K., et al. Expression of tissue factor and tissue factor pathway inhibitor in rat lungs with lipopolysaccharide-induced disseminated intravascular coagulation. Lab Invest. 77:1997;581-589.
20. Nishio K., Akai Y., Murao Y., et al. Increased plasma concentrations of adrenomedullin correlate with relaxation of vascular tone in patients with septic shock. Crit Care Med. 25:1997;953-957.
21. Marustuka K., Asada Y., Hatakeyama K., et al. Effects of adrenomedullin on coagulation/fibrinolysis factors in cultured human aortic endothelial cells. Second International Symposium on Adrenomedullin and PAMP, Miyazaki, Japan. 2000;40. Abstract.
22. Valentin S., Nordfang O., Bregengard C., Wildgoose P. Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins. Blood Coagul Fibrinolysis. 4:1993;713-720.
23. Mast A.E., Higuchi D.A., Huang Z.-F., et al. Glypican-3 is a binding protein on the Hep G2 cell surface for tissue factor pathway inhibitor. Biochem J. 327:1997;577-583.
24. Kamikubo Y., Nakahara Y., Takemoto S., et al. Human recombinant tissue-factor pathway inhibitor prevents the proliferation of cultured human neonatal aortic smooth muscle cells. FEBS Lett. 407:1997;116-120.
25. Warshawsky I., Herz J., Broze G.J. Jr., Schwartz A.L. The low density lipoprotein receptor-related protein can function independently from heparan sulfate proteoglycans in tissue factor pathway inhibitor endocytosis. J Biol Chem. 271:1996;25873-25879.
26. Narita M., Bu G., Olins G.M., et al. Two receptor system are involved in the plasma clearance of tissue factor pathway inhibitor in vivo. J Biol Chem. 270:1995;24800-24804.
27. Valentin S., Larnkjer A., Ostergaard P., Nielsen J.I., Nordfang O. Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans. Thromb Res. 75:1994;173-183.
28. McLatchie L.M., Fraser N.J., Main M.J., et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature. 393:1998;333-339.
29. Muff R., Leuthauser K., Buhlmann N., et al. Receptor activity modifying proteins regulate the activity of a calcitonin gene-related receptor in rabbit aortic endothelial cells. FEBS Lett. 441:1998;366-368.
30. Eto T., Samson W.K. Adrenomedullin and proadrenomedullin N-terminal 20 peptide: vasodilatory peptides with multiple cardiovascular and endocrine actions. Trends Endocrinol Metab. 12:2001;91-93.
31. Shimizu K., Tanaka H., Sunamori M., Marumo F., Shichiri M. Adrenomedullin receptor antagonism by calcitonin gene-related peptide (8-37) inhibits carotid artery neointimal hyperplasia after balloon injury. Circ Res. 85:1999;1199-1205.
32. Kamitani S., Asakawa M., Shimekake Y., et al. The RAMP2/CRLR complex is a functional adrenomedullin receptor in human endothelial and vascular smooth muscle cells. FEBS Lett. 448:1999;111-114.
33. Autelitano D.J., Ridings R. Adrenomedullin signalling in cardiomyocytes is dependent upon CRLR and RAMP2 expression. Peptides. 22:2001;1851-1857.
34. Hinson J.P., Kapas S., Smith D.M. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev. 21:2000;138-167.
35. Belloni A.S., Andreis P.G., Rossi G.P., et al. Inhibitory effects of adrenomedullin (ADM) on the aldosterone response of human adrenocortical cells to angiotensin-II: role of ADM(22-52)-sensitive receptors. Life Sci. 63:1998;2313-2321.
36. Kato J., Kitamura K., Kangawa K., Eto T. Receptor or adrenomedullin in human vascular endothelial cells. Eur J Pharmacol. 289:1995;383-385.